Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Arthritis Care & Research|February 11, 2011
Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trialChi Chiu Mok, Chun Kwok Wong, Chi Hung To, et al.
The Open Rheumatology Journal|December 18, 2008
Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective studyLing Yin Ho, Chi Chiu Mok, Chi Hung To, et al.
Medicine|July 17, 2007
Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative studyChi Chiu Mok, Ka Hang Tong, Chi Hung To, et al.
Annals of the Rheumatic Diseases|May 26, 2020
Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritisChi Chiu Mok, Ling Yin Ho, Shirley King Yee Ying, et al.
Arthritis Care & Research|October 5, 2010
Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritisChi Chiu Mok, Gary Tin Choi Ko, Ling Yin Ho, et al.
Annals of the Rheumatic Diseases|January 1, 2015
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-upChi Chiu Mok, King Yee Ying, Cheuk Wan Yim, et al.
Annals of the Rheumatic Diseases|December 29, 2010
Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trialChi Chiu Mok, King Yee Ying, Chi Hung To, et al.
The American Journal of Medicine|March 28, 2006
Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamideChi Chiu Mok, King Yee Ying, Woon Leung Ng, et al.
Clinical and Experimental Rheumatology|February 20, 2025
Tixagevimab-cilgavimab for the prevention of COVID-19: real-world experience in patients with rheumatic diseases receiving rituximabChi Chiu Mok, Moon Ho Leung, Ka Man Chan, et al.
Rheumatology (Oxford, England)|May 2, 2023
Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics RegistryChi Chiu Mok, Ho So, Cheuk Wan Yim, et al.
Pageof 4